Literature DB >> 9444565

Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease.

J Lan1, D H Jiang.   

Abstract

In this study a chronic cerebral iron-loaded model was established by feeding mice with high iron diet. Data indicated that brain iron concentrations were significantly increased in iron-fed mice compared with those of controls. A significant increase in oxidized glutathione (GSSG), decrease in total glutathione (oxidized and reduced glutathione, GSSG + GSH), and therefore increase in the GSSG/(GSSG + GSH) ratios were observed in iron-loaded mice. Hydroxyl radical (.OH) levels in striatum and brainstem were also significantly increased. Excessive iron alone did not change either dopamine (DA) or lipid peroxidation (LPO) concentrations in striatum. However, a single injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30 mg/kg, i.p.) into the iron-loaded mice caused a great enhancement in all these biochemical abnormalities. These findings suggest that iron does induce oxidative stress, but not severely injury neurons per sc. Excessive iron accumulation in the brain, however, is a potential risk for neuronal damage, which may promote by triggering factor(s). This supports the hypothesis that excessive cerebral iron may contribute to the aetiology of Parkinson's disease (PD).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9444565     DOI: 10.1007/BF01291883

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  50 in total

1.  Neurochemical perspectives to the function of monoamine oxidase.

Authors:  P Riederer; C Konradi; G Hebenstreit; M B Youdim
Journal:  Acta Neurol Scand Suppl       Date:  1989

2.  The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium.

Authors:  G E Kass; J M Wright; P Nicotera; S Orrenius
Journal:  Arch Biochem Biophys       Date:  1988-02-01       Impact factor: 4.013

3.  Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  T P Singer; N Castagnoli; R R Ramsay; A J Trevor
Journal:  J Neurochem       Date:  1987-07       Impact factor: 5.372

Review 4.  Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.

Authors:  P Jenner
Journal:  Acta Neurol Scand Suppl       Date:  1993

5.  Determination of malonaldehyde precursor in tissues by thiobarbituric acid test.

Authors:  M Mihara; M Uchiyama
Journal:  Anal Biochem       Date:  1978-05       Impact factor: 3.365

6.  Glutathione and ascorbate during ischemia and postischemic reperfusion in rat brain.

Authors:  A J Cooper; W A Pulsinelli; T E Duffy
Journal:  J Neurochem       Date:  1980-11       Impact factor: 5.372

7.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.

Authors:  E Sofic; P Riederer; H Heinsen; H Beckmann; G P Reynolds; G Hebenstreit; M B Youdim
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

8.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

Review 9.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Authors:  M Gerlach; P Riederer; H Przuntek; M B Youdim
Journal:  Eur J Pharmacol       Date:  1991-12-12       Impact factor: 4.432

10.  Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra.

Authors:  G J Sengstock; C W Olanow; A J Dunn; S Barone; G W Arendash
Journal:  Exp Neurol       Date:  1994-11       Impact factor: 5.330

View more
  19 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.

Authors:  Julie K Andersen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 3.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

Review 4.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

5.  The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2.

Authors:  Michela Campolo; Giovanna Casili; Flavia Biundo; Rosalia Crupi; Marika Cordaro; Salvatore Cuzzocrea; Emanuela Esposito
Journal:  Antioxid Redox Signal       Date:  2017-01-27       Impact factor: 8.401

6.  The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease.

Authors:  M Thiruchelvam; E K Richfield; R B Baggs; A W Tank; D A Cory-Slechta
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

7.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

8.  Neurobehavioural deficits following postnatal iron overload: II Instrumental learning performance.

Authors:  T Archer; N Schröder; A Fredriksson
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

9.  Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders.

Authors:  Genaro G Ortiz; Gloria A Benítez-King; Sergio A Rosales-Corral; Fermín P Pacheco-Moisés; Irma E Velázquez-Brizuela
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

Review 10.  Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.

Authors:  Manfred Gerlach; Kay L Double; Dorit Ben-Shachar; Luigi Zecca; Moussa B H Youdim; Peter Riederer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.